AIM
PTCT icon

Aigen Investment Management’s PTC Therapeutics PTCT Stock Holding History

Aigen Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,896
Closed -$402K – 977
2024
Q4 		$402K Buy
+8,896
New +$381K 0.07% 394
2022
Q4 		– Sell
-10,664
Closed -$535K – 724
2022
Q3 		$535K Buy
+10,664
New +$523K 0.08% 297
2020
Q2 		– Sell
-31,954
Closed -$1.43M – 1195
2020
Q1 		$1.43M Buy
31,954
+9,564
+43% +$482K 0.19% 143
2019
Q4 		$1.07M Buy
+22,390
New +$951K 0.18% 165

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's PTCT Position: Q1 2025 in Review

Aigen Investment Management sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 8,896 shares — an estimated $402K sold.

Aigen Investment Management first reported a position in PTCT in Q4 2019 and held it in 4 quarters. The position peaked at $1.43M in Q1 2020. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

  • Aigen Investment Management reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aigen Investment Management sold 8,896 PTC Therapeutics shares in Q1 2025, an estimated $402K.
  • Aigen Investment Management first reported a position in PTC Therapeutics in Q4 2019 and held it in 4 quarters.
  • Aigen Investment Management's PTC Therapeutics position peaked at $1.43M in Q1 2020.
  • 260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.